Decline in sales volume of pharmaceutical products and quasi-drugs
First written in FY2018-Q1. 6 of 11 entries say "Restated". Latest entry: FY2026-H1.
0 other companies' latest entry also says "Dropped".
- FY2026-H1DroppedAnnual reportThe performance explanation for the Functional Materials segment for the current interim consolidated accounting period made no specific mention of pharmaceutical intermediate sales volumes and did not state that they had changed from an increase to a decrease.
- FY2024-Q1Pharmaceutical intermediate sales volumes reversed from an increase to a decreaseAnnual report
「This was due mainly to lower sales volumes of electronic gases, pharmaceutical intermediates, latex products and other products, as well as higher fixed costs and other factors.」
Although an increase in pharmaceutical intermediate sales volumes had been disclosed through the previous fiscal year as a factor contributing to higher revenue and operating profit in the Functional Chemicals and Functional Materials businesses, a decline in sales volumes became a factor contributing to lower profit in the first quarter of the current fiscal year. - FY2022RestatedAnnual report
「This was due mainly to higher sales volumes of pharmaceutical intermediates, functional products and powder resins, as well as foreign exchange effects and other factors.」
The trend from lower pharmaceutical product sales in prior fiscal years to higher pharmaceutical intermediate sales continued to be disclosed for the full fiscal year. - FY2022-Q3RestatedAnnual report
「This was due mainly to higher sales volumes of pharmaceutical intermediates, functional products and powder resins.」
The trend from lower sales of pharmaceutical and medical products described in prior fiscal years to higher pharmaceutical intermediate sales continued, and the increase in pharmaceutical intermediate sales volumes was also disclosed for the current quarter. - FY2022-Q1RestatedAnnual report
「This was due mainly to higher sales volumes of pharmaceutical intermediates, latex products and powder resins.」
The trend changed from lower pharmaceutical product sales to higher pharmaceutical intermediate sales, and the increase in pharmaceutical intermediate sales volumes was also disclosed for the current quarter. - FY2021From lower pharmaceutical product sales to higher pharmaceutical intermediate salesAnnual report
「This was due mainly to higher sales volumes of latex products and pharmaceutical intermediates.」
The disclosure changed from the decline in sales volumes of pharmaceutical and medical products described in prior fiscal years to an increase in sales volumes of pharmaceutical intermediates in the current fiscal year. - FY2019-Q1DroppedAnnual reportThe explanation of the Chemicals segment for the first quarter did not mention the previously disclosed decline in sales volumes of pharmaceutical products and medical products.
- FY2018RestatedAnnual report
「This was due mainly to higher shipments of microparticle polymers and other products, despite lower sales of pharmaceutical products.」
The decline in pharmaceutical product sales continued to be disclosed as a factor contributing to lower full-year revenue and operating profit in the Chemicals segment. - FY2018-Q3RestatedAnnual report
「This was due mainly to higher sales volumes of microparticle polymers and other products, despite lower sales volumes of medical products.」
The decline in sales volumes of medical products continued to be disclosed as a factor contributing to lower profit in the Chemicals segment. - FY2018-Q2RestatedAnnual report
「This was attributable to sales volumes of fine-particle polymers and other products being broadly in line with the same period of the previous fiscal year, while sales volumes of pharmaceutical products declined, among other factors.」
The decline in sales volumes of pharmaceutical products continued to be disclosed as a factor contributing to lower revenue and operating profit in the Chemicals segment. - FY2018-Q1First statedAnnual report
「This was attributable to increased sales of fine-particle polymers and other products, while sales volumes of pharmaceutical products and other products declined.」
The decline in sales volumes of pharmaceutical products and other products was disclosed for the first time as a factor contributing to lower revenue and operating profit in the Chemicals segment.